VolitionRx's Biomarker Selected for French Sepsis Detection Initiative

VolitionRx Ltd. announced that its Nu.Q NETs H3.1 assay has been selected as the exclusive biomarker for "DETECSEPS," a French government-funded initiative evaluating early sepsis detection methods. The program, part of the France 2030 plan, is led by the IHU SEPSIS and supported by a €6.3 million grant aimed at transforming emergency care for patients with infection and sepsis risk. Professor Djillali Annane, Scientific Director of DETECSEPS, explained that combining Volition's biomarker with the clinical NEWS2 score could significantly improve early sepsis identification in emergency settings. He noted that H3.1 shows strong correlation with disease severity and provides excellent prognostic utility for outcomes including organ failure and mortality. The biomarker's prognostic power at ICU admission reportedly exceeded established severity scores such as APACHE II and SOFA.

Dr. Andrew Retter, Volition's Chief Medical Officer, emphasized the practical implications of the technology, stating that the biomarker can deliver results within one hour using the Immunodiagnostic Systems i10 automated analyzer. This rapid turnaround time could enhance emergency decision-making processes. The company believes earlier sepsis identification could save lives, improve survivors' quality of life, and reduce healthcare system burdens. The selection represents a significant validation of Volition's epigenetic approach to disease detection. The company is providing the Nu.Q H3.1 Assay pro-bono to support this national evaluation, demonstrating commitment to advancing sepsis care. For additional information about Volition's work, visit https://www.Volition.com. The DETECSEPS program reflects growing recognition of sepsis as a critical healthcare challenge requiring improved diagnostic tools.

Sepsis remains a leading cause of hospital mortality worldwide, with early detection being crucial for effective treatment. Traditional diagnostic methods often lack the speed and accuracy needed in emergency situations. The French initiative's focus on biomarker technology highlights a shift toward molecular diagnostics in critical care. Successful implementation could establish new standards for sepsis management across healthcare systems. The collaboration between Volition and French healthcare authorities represents a model for public-private partnerships in medical innovation. By integrating biomarker testing with clinical assessment tools, the approach aims to create more reliable early warning systems. As the DETECSEPS evaluation progresses, findings could influence sepsis protocols beyond France, potentially benefiting patients globally through improved detection methodologies.